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More detailed examination of the sentinel lymph node (SLN) in breast cancer has raised concerns about the clin-
ical significance of micrometastases, specifically isolated tumor cells detected only through immunohistochemical (IHC) staining.
It has been suggested that these cells do not carry the same biologic implications as true metastatic foci and may represent artifact.
A retrospective institutional review board-approved review was conducted on clinically node-negative breast cancer patients who
underwent SLN biopsy (SLNB) between 1997 and 2003. Retrospective analysis of tumor characteristics and the method of the
initial diagnostic biopsy were correlated with the presence and nature of metastatic disease in the SLN. Of 537 SLNBs, 123 (23%)
were hematoxylin-eosin (H&E) positive. SLN positivity strongly correlated with tumor size (p < 0.001) and tumor grade (p = 0.025),





 = 381). Of the 291 H&E-negative patients, 26 had IHC-only detected micrometastases (9%). The likelihood of detecting
IHC-only metastases did not correlate with tumor size or grade, but was significantly higher in patients undergoing excisional biopsy
than core needle biopsy. While the method of biopsy has no demonstrable effect on the likelihood of finding metastases in the
SLN by routine serial sectioning and H&E staining, it may significantly impact the likelihood of finding micrometastases by IHC.
IHC should not be used routinely in the evaluation of the SLN and caution should be used when basing treatment decisions (com-
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ntraoperative lymphatic mapping and sentinel lymph
node biopsy (SLNB) has now become the standard of
care in the axillary examination of patients with breast
cancer. More accurate and less invasive than axillary dis-
section, it rapidly changed the management of breast can-
cer and has spared countless women the lymphedema and
other morbidities associated with a complete node dissec-
tion (1,2). However, as with all new technologies, SLNB
is not without its questions.
Sentinel lymph node biopsy is more sensitive than axil-
lary node dissection in that it allows for detailed exami-
nation of the sentinel node by serial sectioning (3,4).
While this improves accuracy, it also raises concerns
about the clinical significance of micrometastases, specif-
ically in patients with isolated tumor cells detected
through immunohistochemical (IHC) staining. It is
possible that we may be detecting tumor cells in the sentinel
lymph nodes (SLNs) that don’t carry the same biologic
implications as true metastatic foci. Why would these cells
be present in the SLN if not for having gained the ability
to metastasize?
One possibility is that tumors routinely shed cells into
the lymphatic vasculature that will never develop into
metastatic lesions. Another possibility is that instrumen-
tation of the tumor, as is done with a needle or excisional
biopsy, might displace tumor cells into the lymph node.
Several authors have demonstrated the possibility that
manipulation of the tumor could physically disperse
tumor cells that might travel via lymphatic pathways to
the regional lymph nodes (5–8). If this is the case, it might
be true that the presence of micrometastases in the sentinel
node may have more to do with the method of biopsy than




A retrospective institutional review board-approved








breast cancer patients who underwent SLNB from
October 1997 to December 2003. Retrospective analysis
was conducted of patient demographics, tumor char-
acteristics, and the method of the initial diagnostic biopsy
(fine-needle aspiration biopsy [FNAB], core needle
biopsy [CNB], or excisional biopsy). It was also recorded
whether the margins around both the invasive cancer and
any in situ component were involved on initial biopsy.
Lymphatic mapping was performed using a variety of
injection techniques using 3–4 mCi technetium-99m and
isosulfan blue dye (lymphazurin, US Surgical, Norwalk, CT).
Lymph nodes with evidence of blue dye uptake or radio-
activity as detected by an intraoperative gamma probe
(Navigator, US Surgical) were labeled as sentinel nodes, as
were lymph nodes that appeared suspicious on exploration.
For all patients, the sentinel node was measured and cut
entirely along its longitudinal axis into sections 1.5 to 2
mm thick. The sections were submitted in formalin for
paraffin section histology. Each paraffin block was sec-
tioned at three levels and stained with hematoxylin-eosin
(H&E). Prior to July 2002, the sentinel nodes also under-
went evaluation with IHC for cytokeratin if the H&E
stains did not reveal metastases. Cytokeratin protein
expression was studied by immunohistochemistry using a
keratin cocktail consisting of a mixture of Cam 5.2 (Becton
Dickinson, Franklin Lakes, NJ, U.S.A.) and AEI/3
(Boehringer Mannheim, Mannheim, Germany). For the
purposes of this study, a sentinel node was designated as
positive by IHC only if the metastasis was a group of
tumor cells identified only with the IHC stains.
Statistical significance for binary or categorical covari-
ates was calculated using the chi-squared test, with a p-




Between October 1997 and December 2003, 537
SLNB procedures were performed for invasive breast can-
cer in 531 clinically node-negative patients (528 women
and 3 men). The average age was 54.4 years (range 22–85
years). The majority of tumors were invasive ductal car-
cinoma (84%), including patients with ductal carcinoma
in situ (DCIS) and microinvasion. Lobular carcinoma
accounted for 10%, while the remaining 6% were other
histologies (tubular, medullary, mucinous, and papillary).
The mean tumor size was 14 mm, ranging from micro-
invasive to 7 cm.
More than half of the cancers were diagnosed by core
needle biopsy (52%). This includes core biopsies of pal-
pable masses performed in the office and image-guided
core biopsies of mammographically detected lesions.
Forty-one patients underwent FNAB (8%) and the
remaining 40% were diagnosed by excisional biopsy,
including both excisions of palpable lesions and wire
localized excisional biopsies of nonpalpable lesions. Of
the 215 excisional biopsies performed, 136 (63%) had
either invasive cancer or in situ cancer extending to one
margin, while 79 (37%) had negative margins obtained on
diagnostic biopsy. The method of biopsy varied with the
size of the lesion (Fig. 1).
All 537 procedures had sentinel nodes evaluated by
serial sectioning and H&E staining. A total of 123
patients were positive by these criteria (23%). SLN posi-
tivity strongly correlated with the size of the tumor (Fig. 2).
In addition to tumor size, tumor grade was significantly
associated with the likelihood of finding a positive node
by H&E (Table 1). The presence of estrogen receptors





 did not correlate with node positivity.
When we examined the presence of lymph node
metastases detected by H&E as compared to the method
of biopsy, there was no correlation found. Patients who
underwent needle biopsy, by either FNA or core needle
biopsy, had the same likelihood of having metastases in
the sentinel node as patients who had an excisional
biopsy. When we broke down this group to patients who
had positive margins and those who had negative margins
after excision, we also found no statistically significant
difference in finding metastases.
A different result was obtained when we looked at
IHC-only micrometastases. Of the 537 procedures, 381
Figure 1. Method of biopsy by size of primary tumor. Core needle
biopsy was used more commonly for small lesions (stereotactic core
biopsy) or large lesions (percutaneous core biopsy) while both
core biopsy and excisional biopsy were utilized equally for lesions
between 1 and 2 centimeters.
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were done prior to July 2002, when we abandoned the
routine use of IHC. Of these 381 patients, 90 (24%) had
H&E-positive sentinel nodes, leaving 291 patients who
were H&E negative. Of these 291 patients, 26 had
micrometastases detected by IHC only (9%). In this case,
the likelihood of detecting IHC-only micrometastases did
not correlate with tumor size or grade (Table 2). As with




 status also did not correlate with finding micrometastases.
However, a statistically significant increase in IHC-only
micrometastases was seen in patients having excisional
biopsy (13%) compared with patients having a needle
biopsy (5%). This was the only factor that correlated with
IHC micrometastases. There was no statistically signifi-
cant difference between positive margin and negative mar-




The results of this retrospective study suggest that
while the method of biopsy has no demonstrable effect on
the likelihood of finding metastases in the SLN by routine
serial sectioning and H&E staining, it may significantly
impact the likelihood of finding micrometastases by IHC.
Two previous studies, one from Memorial Sloan-
Kettering Cancer Center (MSKCC) (9) and one from
the John Wayne Cancer Institute (JWCI) (10), also found
a significant correlation between the method of biopsy
and the finding of metastases in the SLN. However, the
two articles had somewhat different findings.
Moore et al. (9), from MSKCC, examined more than
4000 SLN procedures and found that when examining the
sentinel nodes by serial sectioning and H&E, the presence
of metastases correlated with tumor size and the presence
Figure 2. Incidence of a positive sentinel lymph node based on the
size of the primary tumor.
Table 1. Factors Associated with a Positive SLNB by
Routine H&E Staining (n = 532)
 
SLN negative SLN positive p
Size
0–5 89 (93%) 7 (7%) <0.001
5–10 128 (89%) 16 (11%)
10–15 99 (82%) 22 (18%)
15–20 51 (60%) 34 (40%)
20–25 23 (50%) 23 (50%)
>25 20 (47%) 21 (53%)
Grade
I 98 (85%) 17 (15%) <0.025
II 162 (75%) 54 (25%)
III 55 (69%) 25 (31%)
ER
Positive 273 (77%) 84 (23%) NS
Negative 79 (73%) 29 (27%)
PR
Positive 226 (77%) 70 (23%) NS
Negative 125 (74%) 43 (26%)
HER-2/neu
Positive 68 (72%) 27 (28%) NS
Negative 238 (77%) 71 (23%)
Biopsy method
Needle 239 (75%) 79 (25%) NS
Excision 170 (79%) 44 (21%)
Margins after excisional biopsy
Positive 104 (78%) 31 (22%) NS
Negative 66 (84%) 13 (16%)
Table 2. Factors Associated with IHC Positivity in
H&E-Negative Lymph Nodes (n = 381)
 
 
SLN IHC negative SLN IHC positive p
Size
0–5 67 (96%) 4 (6%) 0.10
5–10 78 (91%) 8 (9%)
10–15 65 (94%) 4 (6%)
15–20 26 (79%) 7 (21%)
>20 27 (90%) 3 (10%)
Grade
I 65 (98%) 1 (2%) NS
II 92 (88%) 13 (12%)
III 35 (95%) 2 (5%)
ER
Positive 170 (90%) 18 (10%) NS
Negative 45 (92%) 4 (8%)
PR
Positive 149 (90%) 16 (10%) NS
Negative 65 (92%) 6 (8%)
HER-2/neu
Positive 37 (86%) 6 (14%) 0.20
Negative 143 (93%) 11 (7%)
Biopsy method
Needle 146 (95%) 8 (5%) <0.025
Excision 117 (87%) 18 (13%)
Margins after excisional biopsy
Positive 70 (84%) 13 (16%) NS








of lymphovascular invasion (LVI), but not with the
method of biopsy. As they had a significant portion of
patients who underwent surgery based on clinical and
radiographic findings, without tissue biopsy, they had a
control group who had no manipulation of the tumor
prior to the sentinel node procedure (save mammography
or physical examination). When they looked at sentinel
nodes positive only by IHC, they found that size and LVI
were not significant, but the method of biopsy was, with
excisional biopsies having a higher risk than needle bi-
opsies, which had a higher risk than no preoperative biopsy.
Our findings at the University of Michigan, though a
smaller sample size, are almost the same as the findings
from MSKCC. As we routinely do not bring patients to the
operating room without some type of tissue diagnosis, we
have no similar control group to compare to.
On the other hand, Hansen et al. (10), from JWCI,
examined 663 patients who underwent SLNB. As with us,
they do not have a group that did not undergo some type
of preoperative biopsy. They found that on multivariate
analysis, the type of biopsy did correlate with finding
metastases in the sentinel node. However, this was any
type of metastases, including those found on H&E, and
they found that there was a decreased chance of finding
disease in the SLN with excisional biopsy as compared to
either FNAB or core needle biopsy. When they examined
the size of the SLN metastases, FNAB actually favored
macrometastases rather than IHC-detected metastases.
Core needle biopsy showed no difference when compared
to excisional biopsy.
Although there is no clear explanation why the JWCI
findings differ, these results confirm the findings from
MSKCC. Preoperative needle biopsy does not signifi-
cantly increase the likelihood of finding metastases in the
sentinel node when the node is examined by serial section-
ing and H&E, as is the recommendation. In addition,
excisional biopsies with positive margins (suggesting the
tumor has been cut across) do not lead to increased detec-
tion of SLN metastases. These results also imply that IHC-
only detected micrometastases may have more to do with
artifact than with tumor biology. This raises questions
regarding the clinical significance of IHC-only detected
micrometastases.
The addition of IHC to routine H&E examination
will dramatically increase the detection rate of cancer
cells within the SLN (3,11–22). The clinical significance
of these micrometastases remains in question, as retro-
spective studies have suggested no prognostic significance
(17,20,22,23), a correlation with disease-free survival but
not overall survival (18,19,21), or a correlation with over-
all survival (12,15,16). Few of these studies used multi-
variate analysis, so it is difficult to answer the question
from the existing retrospective data. The fact that IHC-
only micrometastases correlate more with the method of
biopsy than with tumor factors known to increase the risk
of true nodal spread further increases the suspicion that
these findings are not clinically significant. Great care
must therefore be taken when using IHC-only micro-
metastases for clinical decision making, as this seems likely
to lead to overtreatment. Unless prospective, randomized
trials prove otherwise, IHC should not be used in the rou-
tine evaluation of sentinel nodes, and if used, patients
found to harbor IHC-only micrometastases (American
Joint Committee on Cancer [AJCC] stage N0(i+)) should
be treated as node negative.
The 2001 Consensus Conference on the Role of
Sentinel Lymph Node Biopsy as well as the College of
American Pathologists have both recommended that
the decision for completion axillary lymph node dissection
(ALND) should not be based on IHC-only micro-
metastases alone (24,25). Of the 26 IHC-only positive
patients in this series, 18 had completion ALND, with
only 1 patient having additional disease in the nonsentinel
nodes. This is comparable to other institution’s experi-
ences with IHC-only positive SLNs. Chu et al. (26)
reported none of 33 patients with IHC-only positive SLNs
had additional disease at completion ALND, and con-
cluded that there is no benefit for patients with T1 or T2
breast cancer and IHC-only micrometastases. Wong et al.
(27) reported 6 of 58 patients with nodal metastases on
completion ALND for IHC-only positive nodes. The
authors concluded that although there may be a slight
decrease in the false-negative rate with the addition of
IHC, it is not significant enough to subject patients to the
morbidity of ALND. Grey et al. (28) found additional dis-
ease in 2 of 28 patients with IHC-only micrometastases in
the SLN. Both patients had advanced lobular tumors.
Not all reports have similar conclusions. Jakub et al.
(29) described 9 of 62 patients with nodal metastases after
completion ALND for IHC-only positive lymph nodes,
12% with T1 lesions, and concluded that IHC should be
considered in all cases to minimize false-negative rates.
The status of the regional lymph nodes remains the
most important prognostic indicator in breast cancer.
Lymphatic mapping, SLNB, and completion ALND for
sentinel node-positive patients have become the standard
of care. Until pending data from prospective trials (Amer-
ican College of Surgeons Oncology Group [ACOSOG]
Z0010 and Z0011) are available, it is still recommended
that patients with positive SLNs as detected by routine
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H&E staining methods undergo completion ALND. The
clinical significance of IHC-only positive nodes remains in
question.
Based on our results and the growing body of evidence,
we recommend against the routine use of IHC in the
pathologic evaluation of breast cancer SLNs. For patients
who have IHC-only metastases, we recommend a multi-
disciplinary approach, with patient counseling on the
unclear clinical significance, and do not recommend
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